Avanos Medical (NYSE:AVNS - Get Free Report) updated its fourth quarter earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $0.38-0.43 for the period, compared to the consensus estimate of $0.40. The company issued revenue guidance of $175-180 million, compared to the consensus revenue estimate of $177.25 million. Avanos Medical also updated its Q4 2024 guidance to 0.380-0.430 EPS.
Avanos Medical Stock Up 4.2 %
Shares of NYSE AVNS traded up $0.64 during trading hours on Monday, hitting $15.84. The stock had a trading volume of 745,714 shares, compared to its average volume of 862,859. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. Avanos Medical has a 52 week low of $14.98 and a 52 week high of $25.36. The firm's 50-day moving average price is $17.84 and its two-hundred day moving average price is $20.93. The company has a market capitalization of $727.96 million, a P/E ratio of 46.59 and a beta of 0.99.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered shares of Avanos Medical from a "strong-buy" rating to a "buy" rating in a report on Sunday, November 3rd.
Get Our Latest Research Report on Avanos Medical
About Avanos Medical
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Further Reading
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
